| Literature DB >> 33734319 |
Kaichun Li1,2, Qiaoyun Wang1, Yanyan Lu1, Xiaorong Pan1, Long Liu2, Shiyu Cheng2, Bingxiang Wu2, Zongchang Song2, Wei Gao1.
Abstract
BACKGROUND: The aim of the present study was to confirm the role of Brachyury in breast cancer and to verify whether four types of machine learning models can use Brachyury expression to predict the survival of patients.Entities:
Keywords: Brachyury; Breast cancer; decision tree; machine learning
Mesh:
Substances:
Year: 2021 PMID: 33734319 PMCID: PMC8024874 DOI: 10.1042/BSR20203391
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Expression of Brachyury protein in breast cancer and paracancerous tissues
| Negative | Positive | X_square | |||
|---|---|---|---|---|---|
| Tumor | 303 | 209(68.98) | 94(31.02) | 4.5181 | 0.0335 |
| Paracancerous | 29 | 26(89.66) | 3(10.34) |
Figure 1Expression of Brachyury protein in breast cancer tissues and paracancerous tissues
(A) cancer tissue +, (B) cancer tissue ++, (C) cancer tissue +++, and (D) paracancerous tissue +
Expression of Brachyury protein in paired cases of breast cancer and paracancerous tissues
| Negative | Positive | X_square | |||
|---|---|---|---|---|---|
| Paracancerous negative | 12(42.86) | 13(46.43) | 25(89.29) | 8.6429 | 0.0033 |
| Paracancerous positive | 1(3.57) | 2(7.14) | 3(10.71) | ||
| 13(46.43) | 15(53.57) | 28(100) |
Figure 2Survival values of Brachyury expression generated by the Kaplan–Meier (KM) plotter
Relationship between Brachyury protein expression and clinical pathological parameters of breast cancer
| Negative | Positive | X2 | |||
|---|---|---|---|---|---|
| Age | Median age | 53(30–83) | 54(30–84) | 0.1302 | |
| AJCC stage | |||||
| Stage:1 | I | 43(63.24) | 25(36.76) | 1.9009 | 0.3866 |
| Stage:2 | II | 112(69.14) | 50(30.86) | ||
| Stage:3 | III | 54(73.97) | 19(26.03) | ||
| Histological stage | |||||
| Hyphology_class_new_y:1 | I | 4(66.67) | 2(33.33) | 0.1568 | 0.9246 |
| Hyphology_class_new_y:2 | II | 147(69.67) | 64(30.33) | ||
| Hyphology_class_new_y:3 | III | 58(67.44) | 28(32.56) | ||
| Menstrual status | |||||
| Menopause:0 | Menopause | 111(65.29) | 59(34.71) | 2.0783 | 0.1494 |
| Menopause:1 | Not menopausal | 98(73.68) | 35(26.32) | ||
| Tumor size | |||||
| Tumor_max_diameter: ≤2 cm | ≤2 cm | 75(65.79) | 39(34.21) | 3.2908 | 0.1929 |
| Tumor_max_diameter: 2.1–5 cm | 2.1–5 cm | 116(69.05) | 52(30.95) | ||
| Tumor_max_diameter: >5 cm | >5 cm | 18(85.71) | 3(14.29) | ||
| Lymph node metastasis | |||||
| Lymph_node: 0 | 0 | 118(69.41) | 52(30.59) | ||
| Lymph_node: 1–3 | 1–3 | 45(67.16) | 22(32.84) | ||
| Lymph_node: 4–9 | 4–9 | 27(77.14) | 8(22.86) | ||
| Lymph_node: ≥10 | ≥10 | 19(61.29) | 12(38.71) | 2.0645 | 0.5591 |
| Molecular type | |||||
| Molecular.type: 1 | Luminal A | 48(60.76) | 31(39.24) | 8.1353 | 0.0433 |
| Molecular.type: 2 | Luminal B | 7(58.33) | 5(41.67) | ||
| Molecular.type: 3 | Her2 overexpression | 31(86.11) | 5(13.89) | ||
| Molecular.type: 4 | Triple negative | 123(69.89) | 53(30.11) | ||
| ER | |||||
| ER_value_new_y: 1 | - | 154(72.64) | 58(27.36) | 3.8781 | 0.0489 |
| ER_value_new_y: 2 | + | 55(60.44) | 36(39.56) | ||
| PR | |||||
| PR_value_new_y: 1 | - | 184(70.5) | 77(29.5) | 1.5556 | 0.2123 |
| PR_value_new_y: 2 | + | 25(59.52) | 17(40.48) | ||
| Her2 | |||||
| HER2: - | - | 137(65.55) | 72(34.45) | 3.1985 | 0.0737 |
| HER2: + | + | 72(76.6) | 22(23.4) |
Figure 3Pearson correlation matrix of data of patient with breast cancer
Figure 4ROC curves used to assess model performance
(A) Decision tree (B) Logistic regression (C) Neural network (D) Random forest